An NGS-based Guardant360 (G360; Guardant Health) study identified KIF5B-RET fusions that are highly specific to NSCLC, whereas non-KIF5B-RET fusions contributed to anti-EGFR therapy resistance [73]. Here, RET is linked to non-small cell lung carcinoma.